the guise of 3 Formyl Rifa SV have come to the notice of his Ministry;

(c) whether it is a fact that Rifampicin was being sold at Rs. 2400 per Kg. upto August, 1988, when the import content was $ 209 per Kg. in domestic production; and

(d) if so, what steps have been taken by his Ministry to investigate the matter?

THE MINISTER OF INDUSTRY (SHRIJ. VENGAL RAO): (a) Yes, Sir.

<b) No, Sir.

(c) and (d) The price of Rifampicin bulk drug was fixed at Rs. 3098 per Kg. in October. 1988 based on the recommendation of BICP and was subsequently reduced to Rs. 3000 per Kg. in January, 1987 and further reduced to Rs. 2500 per Kg. on 28-9-1988. International prices of bulk drugs and intermediates fluctuate widely from time to time.

Report about the Categorisation ol Vitamins

1430 SHRI RAOOF VALIULLAH: Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 353 given in the Rajya Sabha on the 22nd August, 1988 and state:

(a) whether it is a fact that Kelkar Committee recommended that combination of vitamin formulations would be price controlled whereas single ingredient vitamin formulations would be price decontrolled;

(b) whether it is a fact that the list of category II bulk drugs recommended by Kelkar Committee includes Vitamins A, Bl, B2, C and B6, etc.

(c) whether it is also a fact that vitamin bulk drugs were price decontrolled by the Ministry at their own level and this resulted in steep increases in their prices;

(d) whether it is also a fact that Kelkar Committee has submitted supplementary report after removing discrepencies and anomalies;

(e) when was the report submitted and what are their recommendations in respect of bulk vitamins;

(f) what are the details of main recommendations and what are the names of bulk dmigs which have been recommended for inclusion on the basis of representations?

THE MINISTER OF INDUSTRY (SHRIJ. VENGALRAO): (a) to (c) The Kelkar Committee recommended that all vitamins when used in combinations would *come* under category II of price control and that (if used singly would not be price controlled. Keeping in view these recommendations, bulk vitamins were kept out of control. However Vitamins A and C are since being brought under price conrtol;

(d) to (f) The Supplementary report submitted by the Kelkar Committee is under examination.

Details of Overcharging

1431. SHRI ASHOK NATH VERMA; Will the Minister of INDUSTRY be pleased to refer to the answer to Starred Question 394 given in the Rajya Sabha on the 29th August, 1988 and state;

(a) when was the details in regard to overcharging asked in respect to the drugs mentioned under Annexure-I alongwith the names of drug companies from whom details were called;

(b) the names of the companies who provided the details;

(c) whether it is a fact that the most of the companies did not respond;

(d) if so, what action was taken by his Ministry against such companies so as to obtain the details;

(e) whether his Ministry worked out the amount due from each due to overcharging;

(f) if so, what are the details thereof; and

(g) what are the details of recovery in these cases upto 31st October, 1988?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO); (a) to (g) Notices for assesing the amount recoverable from the companies were issued between 1984 and 1987. The details of drugs and names of the companies producing them are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved. Necessary action is taken to recover the amounts as per due process of law.

Sales turn over of price decontrolled Formulations

1432. SHRI ASHOK NATH VERMA; Will the Mfinister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3288 given in the Rajya Sabha on the 22nd August, 1988 and state:

(a) whether it is a fact that formulators are providing the sales turn over of pric$_e$ decontrolled fomulations to his Ministry according to Drugs Price Control Order, 1987;

(b) if so, what was the sales turn over provided by the major formula-tors of Isoxuprine Hcl. Polymixin-B-Sulphate, Flucort formulations, Phe-nforlmin, Durabolin; Decadurabolin. Glipizide and Pancretine in forms submitted to his Ministry;

(c) whether it is a fact that his Ministry is subscribing for ORG which provides sales turn over on selected basis;

(d) if so, what was the sales turn over provided under ORG for these formulations for last two years; and

(e) how many persons in his Ministry are engaged in monitoring of drugs and what aspects do they monitor?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Manufacturers are required to furnish information as per the provisions of Drugs (Price Control) Order, 1987.

(b) to (d) Sales turnover of formulations is not monitored.

(e) Various officials are involved in monitoring the price movements of drugs.

Overcharging of Baralgon

1433. SHRI DHARANIDHAR BASUMATARI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the amount due on account of overcharg ing on Baralgon alone should come more than 12 crores and more than five crores and mor$_e$ than five crores in respect of other drugs upto Dece mber, 1983;

(b) what are the details of price charged and price fixed along with production of each from the date of litigation and rate on which calculation was made;

(c) whether it is a fact that the amount assessed is only upto December, 1983 and not the total amount;

(d) whether it is also a fact that the relevant date for production and litigation is 1st January, 1981 and not 1982-83;

(e) whether it is also a fact that the assessment made by the company is totally incorrect; and

(f) if so, what steps have been taken to review the matter and fix responsibility?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO)' (a> to (f) The required information, to the extent available would be collected and [1] laid on the Table of the House.